Showing 1 - 10 of 922
Purpose: US policy makers have been looking at various ways to curb rising health care costs in USA, including ways to promote the use of generic drugs in lieu of brand drugs. In this broader context, the implementation of Patient Protection and Affordable Care Act (ACA) in December 2013 will...
Persistent link: https://www.econbiz.de/10014036939
This paper studies how gifts - monetary or in-kind payments - from drug firms to physicians in the US affect prescriptions and drug costs. We estimate heterogeneous treatment effects by combining physician-level data on antidiabetic prescriptions and payments with causal inference and machine...
Persistent link: https://www.econbiz.de/10014249570
Reference prices constitute a main determinant of patient health care reimbursement in many countries. We study the effects of a change from an "external" (based on a basket of prices in other countries) to an "internal" (based on comparable domestic products) reference price system. We find...
Persistent link: https://www.econbiz.de/10010339324
Persistent link: https://www.econbiz.de/10010483181
Governments worldwide are increasingly concerned about the booming CBD (cannabidiol) products. However, little is known about the impact of their liberalization. We study a unique case of unintended liberalization of a CBD-based product (light cannabis) that occurred in Italy in 2017. Using...
Persistent link: https://www.econbiz.de/10012839052
Persistent link: https://www.econbiz.de/10011815606
Persistent link: https://www.econbiz.de/10014461499
To examine the drivers of innovation, this paper studies the global R and D effort to fight the deadliest diseases and presents four results. We find: (1) global pharmaceutical R and D activity-measured by clinical trials-typically follows the 'law of diminishing effort': id est the elasticity...
Persistent link: https://www.econbiz.de/10012518690
Persistent link: https://www.econbiz.de/10012501487
To examine the drivers of innovation, this paper studies the global R&D effort to fight the deadliest diseases and presents four results. We find: (1) global pharmaceutical R&D activity - measured by clinical trials - typically follows the 'law of diminishing efforts': i.e. the elasticity of R&D...
Persistent link: https://www.econbiz.de/10012430944